Michael Gardner

Mr. Michael Gardner

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2017 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Open access
MGMichael Gardner
Michael Gardner
LMLisa G. McWilliams
Lisa G. McWilliams
JJJeffrey I. Jones
Jeffrey I. Jones
ZKZsuzsanna Kuklenyik
Zsuzsanna Kuklenyik
JPJames L. Pirkle
James L. Pirkle
JBJohn Barr
John Barr
We demonstrate the application of in-source nitrogen collision-induced dissociation (CID) that eliminates the need for ester hydrolysis before simultaneous analysis of esterified cholesterol (EC) a...

8 October 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
AIAnna A Ivanova
Anna A Ivanova
JRJon C. Rees
Jon C. Rees
BPBryan A. Parks
Bryan A. Parks
MAMichael Andrews
Michael Andrews
MGMichael Gardner
Michael Gardner
JBJohn Barr
John Barr
Aberrations in lipid and lipoprotein metabolic pathways can lead to numerous diseases, including cardiovascular disease, diabetes, neurological disorders, and cancer. The integration of quantitative lipid and lipoprotein profiling of human plasma may provide a powerful approach to inform early disease diagnosis and prevention. In this study, we leveraged data-driven quantitative targeted lipidomics and proteomics to identify specific molecular changes associated with different metabolic risk categories, including hyperlipidemic, hypercholesterolemic, hypertriglyceridemic, hyperglycemic, and normolipidemic conditions. Based on the quantitative characterization of serum samples from 146 individuals, we have determined individual lipid species and proteins that were significantly up- or down-regulated relative to the normolipidemic group. Then, we established protein–lipid topological networks for each metabolic category and linked dysregulated proteins and lipids with defined metabolic pathways. To evaluate the differentiating power of integrated lipidomics and proteomics data, we have built an artificial neural network model that simultaneously and accurately categorized the samples from each metabolic risk category based on the determined lipidomics and proteomics profiles. Together, our findings provide new insights into molecular changes associated with metabolic risk conditions, suggest new condition-specific associations between apolipoproteins and lipids, and may inform new biomarker discovery in lipid metabolism-associated disorders.

Verified
Journal Article
Open access
PDF file
JKJennifer Denise Kusovschi
Jennifer Denise Kusovschi
AIAnna A Ivanova
Anna A Ivanova
MGMichael Gardner
Michael Gardner
RMRobert W. McGarrah
Robert W. McGarrah
WKWilliam E. Kraus
William E. Kraus
JBJohn Barr
John Barr
Designing studies for lipid-metabolism-related biomarker discovery is challenging because of the high prevalence of various statin and fibrate usage for lipid-lowering therapies. When the statin and fibrate use is determined based on self-reports, patient adherence to the prescribed statin dose regimen remains unknown. A potentially more accurate way to verify a patient’s medication adherence is by direct analytical measurements. Current analytical methods are prohibitive because of the limited panel of drugs per test and large sample volume requirement that is not available from archived samples. A 4-min-long method was developed for the detection of seven statins and three fibrates using 10 µL of plasma analyzed via reverse-phase liquid chromatography and tandem mass spectrometry. The method was applied to the analysis of 941 archived plasma samples collected from patients before cardiac catheterization. When statin use was self-reported, statins were detected in 78.6% of the samples. In the case of self-reported atorvastatin use, the agreement with detection was 90.2%. However, when no statin use was reported, 42.4% of the samples had detectable levels of statins, with a similar range of concentrations as the samples from the self-reported statin users. The method is highly applicable in population studies designed for biomarker discovery or diet and lifestyle intervention studies, where the accuracy of statin or fibrate use may strongly affect the statistical evaluation of the biomarker data.

27 February 2026 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
ZKZsuzsanna Kuklenyik
Zsuzsanna Kuklenyik
AIAnna A Ivanova
Anna A Ivanova
LDLauren E. Drinkard
Lauren E. Drinkard
DSDavid M. Schieltz
David M. Schieltz
JJJeffrey I. Jones
Jeffrey I. Jones
JBJohn Barr
John Barr
High-density and low-density lipoproteins (HDL and LDL) are established analytical targets for diagnosis and risk stratification of numerous chronic diseases. This study investigates potential sources of bias in lipoprotein particle counting (HDL-P and LDL-P), focusing on the most atheroprotective small-HDL and most pro-atherogenic small-LDL. Plasma samples were fractionated using asymmetric-flow field-flow fractionation (AF4), coupled with hydrodynamic size measurement and comprehensive liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of each fraction. Concentration-size profiles were deconvoluted into 10 HDL and 8 LDL Gaussian subspecies. Molecular volume ratios were used to evaluate proposed particle models, providing evidence for the presence of s-HDL disk and s-LDL dimers, as sources of bias in calculated HDL-P and LDL-P when spherical particle geometry is assumed. Matching apoA1/HDL-P and apoB/LDL-P to consensus values enabled correction of mass diameters (k*d m ), with k≈1.2 for s-HDL disks, and k≈0.8 for s-LDL dimers. These corrections resulted in closer agreements of the calculated HDL-P and LDL-P values with those reported by nuclear magnetic resonance spectroscopy (n = 666). After corrections, average AF4-LC-MS/MS versus NMR differences decreased from 20 to 4.9% for HDL-P and from −47% to −5.7% for LDL-P; x-y correlations improved from 0.83 to 0.85 and 0.51 to 1.03, respectively; and both platforms showed a dominant presence of s-HDL and s-LDL subclasses. Overall, the results support standardization of clinical methodologies for lipoprotein subclass measurement around apoA1 and apoB, and harmonization of HDL and LDL subclass definitions based on composition and structural characteristics rather than strictly enforced size cutoffs. Graphical abstract